期刊
NATURE CANCER
卷 3, 期 4, 页码 402-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s43018-022-00351-8
关键词
-
类别
资金
- National Cancer Institute [R35CA220497, RO1 CA201049, PO1CA154303]
- American Cancer Society [CRP-17-111-01-CDD]
- Balassiano Family Fund for Lung Cancer Research
- Gohl Family Lung Cancer Research Fund
- Takeda
- Ruth L. Kirschstein National Research Service Award [1F32CA247198-01]
- Japan Society for the Promotion of Science
- Uehara Memorial Foundation
Researchers have discovered a new EGFR inhibitor, JBJ-09-063, which shows efficacy against therapy-resistant mutations in EGFR-mutant lung cancer. The study also found that the resistance to JBJ-09-063 is caused by EGFR homo- or heterodimerization and specific mutations.
Janne and colleagues discover and characterize an allosteric EGFR inhibitor with efficacy against therapy-resistant mutations and show preclinical efficacy as monotherapy and in combination in patient-derived xenograft models. Epidermal growth factor receptor (EGFR) therapy using small-molecule tyrosine kinase inhibitors (TKIs) is initially efficacious in patients with EGFR-mutant lung cancer, although drug resistance eventually develops. Allosteric EGFR inhibitors, which bind to a different EGFR site than existing ATP-competitive EGFR TKIs, have been developed as a strategy to overcome therapy-resistant EGFR mutations. Here we identify and characterize JBJ-09-063, a mutant-selective allosteric EGFR inhibitor that is effective across EGFR TKI-sensitive and resistant models, including those with EGFR T790M and C797S mutations. We further uncover that EGFR homo- or heterodimerization with other ERBB family members, as well as the EGFR L747S mutation, confers resistance to JBJ-09-063, but not to ATP-competitive EGFR TKIs. Overall, our studies highlight the potential clinical utility of JBJ-09-063 as a single agent or in combination with EGFR TKIs to define more effective strategies to treat EGFR-mutant lung cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据